


Please amend the application as follows:

**In the claims:**

Please cancel claims 8 and 9 without prejudice or disclaimer.

Please amend claims 1-7 as follows:

1. (Currently Amended) ~~Novel~~ Peptides of the formula I



where

R<sup>1</sup> is hydrogen, methyl; or ethyl;

R<sup>2</sup> is methyl; or ethyl; or

R<sup>1</sup>-N-R<sup>2</sup> together are a pyrrolidine ring;

A is a valyl, isoleucyl, allo-isoleucyl, 2-tert-butylglycyl, 2-ethylglycyl, norleucyl or norvalyl residue;

B is a N-methyl-valyl, N-methyl-norvalyl, N-methyl-leucyl, N-methyl-isoleucyl, N-methyl-2-tert-butylglycyl, N-methyl-2-ethylglycyl, or N-methyl-norleucyl residue;

D is a prolyl, homoprolyl, hydroxyprolyl, or thiazolidine-4-carbonyl residue;






E is a prolyl, homoprolyl, hydroxyprolyl, thiazolidine-4-carbonyl, trans-4-fluoro-L-prolyl, cis-4-fluoro-L-prolyl, trans-4-chloro-L-prolyl or cis-4-chloro-L-prolyl residue;

X is ethyl, propyl, butyl, isopropyl, sec. butyl, tert.-butyl, cyclopropyl, or cyclopentyl;

G is a L-2-tert.butylglycyl, D-2-terr.butylglycyl, D-valyl, D-isoleucyl, D-leucyl, D-norvalyl, 1-aminopentyl-1-carbonyl, or 2,2-dimethylglycyl residue;

s is 0 or 1;

K is -NH-C<sub>1-8</sub>-alkyl, -NH-C<sub>3-8</sub>-alkenyl, -NH-C<sub>3-8</sub>-alkinyl, -NH-C<sub>6-8</sub>-cycloalkyl, -NH-C<sub>1-4</sub>-alkene-C<sub>3-8</sub>-cycloalkyl, C<sub>1-4</sub>-alkyl-N-C<sub>1-6</sub>-alkyl, in which ~~residues~~ one CH<sub>2</sub> group may be replaced by O or S, one H by phenyl or cyano, or 1, 2 or 3 H by F, except the N-methoxy-N-methylamino, N-benzylamino, or N-methyl-N-benzylamino residue, or K is



and the salts thereof with physiologically tolerated acids.

2. (Currently Amended) ~~Novel~~ Peptides of the formula I



where

$\text{R}^1$  is hydrogen, methyl; or ethyl;

$\text{R}^2$  is methyl; or ethyl ; or

$\text{R}^1\text{-N-R}^2$  together are a pyrrolidine ring;

A is a valyl, isoleucyl, allo-isoleucyl, 2-tert-butylglycyl, 2-ethylglycyl, norleucyl or norvalyl residue;

B is a N-methyl-valyl, N-methyl-norvalyl, N-methyl-leucyl, N-methyl-isoleucyl, N-methyl-2-tert-butylglycyl, N-methyl-2-ethylglycyl, or N-methyl-norleucyl residue;

D is a prolyl, homoprolyl, hydroxyprolyl, or thiazolidine-4-carbonyl residue;

E is a prolyl, homoprolyl, hydroxyprolyl, thiazolidine-4-carbonyl, trans-4-fluoro-L-prolyl, cis-4-fluoro-L-prolyl, trans-4-chloro-L-prolyl or cis-4-chloro-L-prolyl residue;

X is ethyl, propyl, butyl, isopropyl, sec. butyl, tert. butyl, cyclopropyl, or cyclopentyl;


G is a L-2-tert.butylglycyl, D-2-terr.butylglycyl, D-valyl, D-isoleucyl, D-leucyl, D-norvalyl, 1-aminopentyl-1-carbonyl, or 2,2-dimethylglycyl residue;


s is 0 or 1;

K -NHCH<sub>3</sub>, -NHCH<sub>2</sub>CH<sub>3</sub>, -NH(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, -NH(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>,  
-NH(CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub>, -NH(CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>, -NH(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>,  
-NHCH(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>, -NHCH(CH<sub>3</sub>)<sub>2</sub>, -NHCH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>,  
-NHCH(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, -NHCH(CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, -NHC(CH<sub>3</sub>)<sub>3</sub>,

-NHCH(CH<sub>2</sub>CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -NHCH(CH<sub>3</sub>)CH(CH<sub>3</sub>)<sub>2</sub>,  
-NHCH(CH<sub>2</sub>CH<sub>3</sub>)CH(CH<sub>3</sub>)<sub>2</sub>, -NHCH(CH<sub>3</sub>)C(CH<sub>3</sub>)<sub>3</sub>,  
-NH-cyclohexyl, -NH-cycloheptyl, -NH-cyclooctyl,  
-N(CH<sub>3</sub>)OCH<sub>2</sub>CH<sub>3</sub>, -N(CH<sub>3</sub>)OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -N(CH<sub>3</sub>)OCH(CH<sub>3</sub>)<sub>2</sub>,  
-N(CH<sub>3</sub>)O(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, -N(CH<sub>3</sub>)OCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, -NH(CH<sub>2</sub>)<sub>2</sub>C<sub>6</sub>H<sub>5</sub>,  
-NH(CH<sub>2</sub>)<sub>3</sub>C<sub>6</sub>H<sub>5</sub>, -NHCH(CH<sub>3</sub>)C<sub>6</sub>H<sub>5</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>5</sub>,  
-NHC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -NHC(CH<sub>3</sub>)(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, -NHCH[CH(CH<sub>3</sub>)<sub>2</sub>]<sub>2</sub>, -  
NHC(CH<sub>3</sub>)<sub>2</sub>CN, -NHCH(CH<sub>3</sub>)CH(OH)C<sub>6</sub>H<sub>5</sub>, -NHCH<sub>2</sub>-cyclohexyl,  
-NHCH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>, -NHCH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -NHCH<sub>2</sub>CF<sub>3</sub>, -NHCH(CH<sub>2</sub>F)<sub>2</sub>, -  
NHCH<sub>2</sub>CH<sub>2</sub>F, -NHCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -NHCH<sub>2</sub>CH<sub>2</sub>SCH<sub>3</sub>,  
-NHCH<sub>2</sub>CHCH<sub>2</sub>, -NH-C(CH<sub>3</sub>)<sub>2</sub>CH=CH<sub>2</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>C≡CH,  
-NHC(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>C≡CH, -NHC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH,  
-NH(CH<sub>2</sub>CH<sub>2</sub>O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
-NHC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>,  
-N(OCH<sub>3</sub>)CH(CH<sub>3</sub>)<sub>2</sub>, -N(OCH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>, -N(OCH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,  
-N(OCH<sub>3</sub>)CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, -N(OCH<sub>3</sub>)C<sub>6</sub>H<sub>5</sub>, -N(CH<sub>3</sub>)OC<sub>6</sub>H<sub>5</sub>,  
-NHCH[CH(CH<sub>3</sub>)<sub>2</sub>]<sub>2</sub>, -N(OCH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,


or K is





and the salts thereof with physiologically tolerated acids.

3. (Currently Amended) ~~Novel~~ Peptides of the formula I



I

where

$R^1$  is hydrogen, methyl; or ethyl;

$R^2$  is methyl; or ethyl ;

A is a valyl, isoleucyl, 2-tert-butylglycyl, 2-ethylglycyl, norleucyl or norvalyl residue;


B is a N-methyl-valyl, N-methyl-norvalyl, N-methyl-isoleucyl, N-methyl-2-tert-butylglycyl, N-methyl-2-ethylglycyl, or N-methyl-norleucyl residue;

D is a prolyl, or thiazolidine-4-carbonyl residue;


E is a prolyl, homoprolyl, thiazolidine-4-carbonyl, trans-4-fluoro-L-prolyl, cis-4-fluoro-L-prolyl, trans-4-chloro-L-prolyl or cis-4-chloro-L-prolyl residue;

- X is ethyl, propyl, isopropyl, sec. butyl, tert.-butyl, or cyclopropyl;  
G is a L-2-tert.butylglycyl, D-2-terr.butylglycyl, D-valyl, D-isoleucyl, D-leucyl, or 2,2-dimethylglycyl residue;  
s is 0 or 1;  
K is -NH-C<sub>1-8</sub>-alkyl, -NH-C<sub>6-8</sub>-cycloalkyl, -NH-CH<sub>2</sub>-cyclohexyl, C<sub>1-4</sub>-alkyl-N-C<sub>1-6</sub>-alkyl, in which ~~residues~~ one CH<sub>2</sub> group may be replaced by O, one H by phenyl or 1 or 2 H by F, except the N-methoxy-N-methylamino, N-benzylamino or N-methyl-N-benzylamino residue, or K is

C1



4. (Currently Amended) ~~Novel~~ Peptides of the formula I



I

where

R<sup>1</sup> is methyl;

R<sup>2</sup> is methyl;

A is a valyl, isoleucyl, 2-tert-butylglycyl, or 2-ethylglycyl;

B is a N-methyl-valyl, N-methyl-isoleucyl, N-methyl-2-tert-butylglycyl, N-methyl-2-ethylglycyl, or N-methyl-norleucyl residue;

D is a prolyl, or thiazolidine-4-carbonyl residue;

E is a prolyl, trans-4-fluoro-L-prolyl, cis-4-fluoro-L-prolyl, trans-4-chloro-L-prolyl or cis-4-chloro-L-prolyl residue;


X is ethyl, isopropyl, sec. butyl, or tert. butyl ;


G is a L-2-tert.butylglycyl, D-2-terr.butylglycyl, D-valyl, D-isoleucyl, D-leucyl, or 2,2-dimethylglycyl residue;

s is 0 or 1;


K is -NH-C<sub>1-8</sub>-alkyl, -NH-C<sub>6-8</sub>-cycloalkyl, -NH-CH<sub>2</sub>-cyclohexyl, C<sub>1-4</sub>-alkyl-N-C<sub>1-6</sub>-alkyl, in which ~~residues~~ one CH<sub>2</sub> group may be replaced by O, one H by phenyl or 1 or 2 H by F, except the N-methoxy-N-methylamino, N-benzylamino or N-methyl-N-benzylamino-residue, or K

is





5. (Currently Amended) ~~Novel~~ Peptides of the formula I



I

where

$R^1$  is methyl;

$R^2$  is methyl;

A is a valyl, isoleucyl, or 2-tert-butylglycyl residue;

B is a N-methyl-valyl, N-methyl-isoleucyl, or N-methyl-2-tert-butylglycyl residue;

D is a prolyl, or thiazolidine-4-carbonyl residue;

E is a prolyl, cis-4-fluoro-L-prolyl or cis-4-chloro-L-prolyl residue;

X is isopropyl, sec. butyl, or tert.-butyl ;


s is 0 or 1;

K is  $-NHC(CH_3)_3$ ,  $-NHCH(CH_2CH_2)CH(CH_3)_2$ ,  $-NHCH(CH_3)C(CH_3)_3$ ,  $-N(CH_3)OCH_2CH_3$ ,  $-N(CH_3)OCH_2CH_2CH_3$ ,  $-N(CH_3)OCH(CH_3)_2$ ,  $-N(CH_3)O(CH_2)_3CH_3$ ,  $-N(CH_3)OCH_2C_6H_5$ ,  $-NHC(CH_3)_2C_6H_5$ ,  $-NHC(CH_3)_2CH_2CH_3$ ,  $-NHC(CH_3)(CH_2CH_3)_2$ ,




-NHCH[CH(CH<sub>3</sub>)<sub>2</sub>]<sub>2</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>CN, -NHCH(CH<sub>3</sub>)CH(OH)C<sub>6</sub>H<sub>5</sub>,  
-NH-C(CH<sub>3</sub>)<sub>2</sub>CH=CH<sub>2</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>C≡CH,  
-NHC(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>C≡CH, -NHC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH,  
-NHC(CH<sub>3</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,  
-NHC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, -N(OCH<sub>3</sub>)CH(CH<sub>3</sub>)<sub>2</sub>, -N(OCH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>,  
-N(OCH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -N(OCH<sub>3</sub>)CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, -N(OCH<sub>3</sub>)C<sub>6</sub>H<sub>5</sub>,  
-N(CH<sub>3</sub>)OC<sub>6</sub>H<sub>5</sub>, -N(OCH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,

or K is



and the salts thereof with physiologically tolerated acids.

6. (Currently Amended) ~~Novel~~ Peptides of the formula I



I


where

R<sup>1</sup> is methyl;

R<sup>2</sup> is methyl;


A is a valyl residue;  
B is a N-methyl-valyl residue;  
D is a prolyl residue;  
E is a prolyl residue;  
X is isopropyl ;  
s is 0 or 1;  
K is -NHC(CH<sub>3</sub>)<sub>3</sub>, -NHCH(CH<sub>2</sub>CH<sub>2</sub>)CH(CH<sub>3</sub>)<sub>2</sub>, -NHCH(CH<sub>3</sub>)C(CH<sub>3</sub>)<sub>3</sub>, -N(CH<sub>3</sub>)OCH<sub>2</sub>CH<sub>3</sub>, -N(CH<sub>3</sub>)OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -N(CH<sub>3</sub>)OCH(CH<sub>3</sub>)<sub>2</sub>, -N(CH<sub>3</sub>)O(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, -N(CH<sub>3</sub>)OCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -NHC(CH<sub>3</sub>) (CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, -NHCH[CH(CH<sub>3</sub>)<sub>2</sub>]<sub>2</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>CN, -NHCH(CH<sub>3</sub>)CH(OH)C<sub>6</sub>H<sub>5</sub>, -NH-C(CH<sub>3</sub>)<sub>2</sub>CH=CH<sub>2</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>C≡CH, -NHC(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>C≡CH, -NHC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, -NHC(CH<sub>3</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -NHC(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, -N(OCH<sub>3</sub>)CH(CH<sub>3</sub>)<sub>2</sub>, -N(OCH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>, -N(OCH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -N(OCH<sub>3</sub>)CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, -N(OCH<sub>3</sub>)C<sub>6</sub>H<sub>5</sub>, -N(CH<sub>3</sub>)OC<sub>6</sub>H<sub>5</sub>, -N(OCH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,

or  $K$  is



and the salts thereof with physiologically tolerated acids.

7. (Currently Amended) ~~Novel~~ Peptides of the formula I



where

$R^1$  is methyl;

$R^2$  is methyl;

A is a valyl, isoleucyl, or 2-tert-butylglycyl residue;

B is a N-methyl-valyl, N-methyl-isoleucyl, or N-methyl-2-tert-butylglycyl residue;

D is a prolyl, or thiazolidine-4-carbonyl residue;

E is a prolyl residue;


X is isopropyl, sec. butyl, or tert.-butyl ;

G is a D-2-tert.butylglycyl, D-isoleucyl, 2,2-dimethylglycyl residue, D-valyl or L-2-tert.butylglycyl;


s is 1;

K is  $-NHCH_3$ ,  $-NHCH_2CH_3$ ,  $-NH(CH_2)_2CH_3$ ,  $-NH(CH_2)_3CH_3$ ,  $-NH(CH_2)_4CH_3$ ,  $-NH(CH_2)_5CH_3$ ,  $-NHCH(CH_3)_2$ ,  $-NHCH(CH_3)CH_2CH_3$ ,  $-NHCH(CH_2CH_3)_2$ ,  $-NHC(CH_3)_3$ ,  $-NH$ -cyclohexyl,  $-NHC(CH_3)_2CN$ ,  $-NCH(CH_3)_2C\equiv CH$  or  $-NHC(CH_3)_2CONH_2$ ;

or K is



or



and the salts thereof with physiologically tolerated acids.

8. (Cancelled)

9. (Cancelled)

10. (Previously Added) The peptide of claim 1, wherein the formula I is  
Me<sub>2</sub>Val-Val-MeVal-Pro-Pro-NHC(CH<sub>3</sub>)<sub>3</sub>.

cl